Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

Phoebe Rich; Christopher Em Griffiths; Kristian Reich; Frank O. Nestlé; Richard K. Scher; Shu Li; Stephen Xu; Ming-Chun Hsu; Cynthia Guzzo

doi:10.1016/j.jaad.2007.07.042

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2008

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Kristian Reich, Frank O. Nestlé, Ying Wu, Mohan Bala, D. Eisenberg, Cynthia Guzzo, Shu Li, Lisa T. Dooley, Christopher Em Griffiths

Article2010

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

Kristian Reich, Jean-Paul Ortonne, Urs Kerkmann, Yanxin Wang, J.‐H. Saurat, Kim Papp, Richard G. Langley, Christopher Em Griffiths

Article2014

Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept

Christopher Em Griffiths, Wolfram Sterry, F Brock, M. Dilleen, D. Stefanidis, Jean‐Michel Germain, Lotus Mallbris

Article2022

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis

Andrew Blauvelt, Melinda Gooderham, Christopher Em Griffiths, April W. Armstrong, Baojin Zhu, Russel Burge, Gaia Gallo, Jiaying Guo, Alyssa Garrelts, Mark Lebwohl

Article2006

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Kristian Reich, Frank O. Nestlé, Kim Papp, J.‐P. Ortonne, Yifang Wu, M Bala, Robert J. Evans, Cynthia Guzzo, Shuangyue Li, Lisa T. Dooley, Christopher Em Griffiths